{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-071350","form_type":"8-K","ticker":"NUVB","cik":"0001811063","company_name":"Nuvation Bio Inc.","filed_at":"2023-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.689267+00:00","generated_at":"2026-06-18T02:19:34.287620+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Nuvation Bio reports Q4 2022 net loss $20.8M, cash $661M; advances NUV-868 and DDC","bullets":["Net loss Q4 2022 $20.8M ($0.10/sh) vs $25.1M ($0.12/sh) Q4 2021; full-year net loss $104.2M.","Cash, equivalents and marketable securities $661.0M as of Dec 31, 2022; no debt disclosed.","R&D expense Q4 2022 $16.9M (down from $22.0M); G&A $7.4M (vs $7.6M) YoY.","Dosed first patient in Phase 1b combo study of NUV-868 with olaparib or enzalutamide; Phase 1 monotherapy ongoing.","Nominated first DDC clinical candidate; expects IND submission by end of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-071350","json":"https://secwatch.observer/filing/0001193125-23-071350.json","markdown":"https://secwatch.observer/filing/0001193125-23-071350.md","text":"https://secwatch.observer/filing/0001193125-23-071350.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811063/000119312523071350/0001193125-23-071350-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811063/000119312523071350/d481540d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T02:19:34.287620+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9675ea55e823dc1c602488f37da373d05cd36972","claim":"Nuvation Bio Inc. reported the fourth quarter and full year ended December 31, 2022 results: net income a net loss of $20.8 million, or $(0.10) per share, EPS $(0.10) per share.","evidence_excerpt":"On March 15, 2023, Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1811063/000119312523071350/0001193125-23-071350-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Net income","value":"a net loss of $20.8 million, or $(0.10) per share"},{"label":"EPS","value":"$(0.10) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}